Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Medsnoscript
WARNING LETTER
•Medsnoscript

Medsnoscript – FDA Warning Letter

Record Details

The FDA issued a Warning Letter to Medsnoscript.com for offering unapproved and misbranded new drugs for sale, specifically "Generic Tamiflu," in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act).

The "Generic Tamiflu" is deemed an unapproved new drug under sections 201(p) and 505(a) of the FD&C Act because it is not generally recognized as safe and effective, and no approved applications exist for it. Its introduction into interstate commerce is prohibited under section 301(d).

Furthermore, the product is misbranded under several sections: - Section 503(b)(1): Offered for sale without requiring a prescription from a licensed practitioner. - Section 502(a): Labeling is false or misleading, implying it is an FDA-approved drug. - Section 502(f)(1): Lacks adequate directions for use by a layman, as it treats conditions not amenable to self-diagnosis and treatment, and is not exempt from this requirement due to its unapproved status.

The FDA emphasizes the inherent risk of unapproved and misbranded drugs, citing potential contamination, counterfeiting, and inconsistent active ingredient levels. The letter requires Medsnoscript.com to immediately cease marketing violative drug products to U.S. consumers and to notify the FDA within 15 working days of corrective actions taken or planned

Company
Medsnoscript
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Howard Sklamberg (Partner)
View Company Profile

ID · 9d2bf231-9af6-4480-b489-8ddb89e71369

Violation Codes10
21 U.S.C. 321(g)FD&C Act 502(a)FD&C Act 502(f)(1)FD&C Act 503(b)(1)FD&C Act 505(a)FD&C Act 301(a)FD&C Act 301(d)21 U.S.C. 352(a)21 U.S.C. 352(f)(1)21 U.S.C. 353(b)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Medsnoscript
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.